SkylineDx Launches a Guideline-Informed Risk Assessment Initiative to Support SLNB Decision-Making in Early-Stage Melanoma

SkylineDx Netherlands United States of America United Kingdom

The Initiative helps clinicians align their clinical practice with updated NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Melanoma (Version 1.2026) frameworkProvides T1b and T2a melanoma patients with a PREDICTIVE molecular test to assess individualized SLN metastasis risklast rev Jan 2026

Differences in Thickness-Specific Incidence and Factors Associated With Cutaneous Melanoma in the US From 2010 to 2018 | Dermatology | JAMA Oncology | JAMA Network Michael L. Chen et al, 2022

TABLE 3, Melanoma Staging - Cutaneous Melanoma - NCBI Bookshelf Chapter 6, Clinical Presentation and Staging of Melanoma, William H. Ward et al, 2017

Melanoma of the Skin — Cancer Stat Facts

Melanoma underreporting among US dermatopathologists: A pilot study - PubMed Heuring E & Chen SC., 2018

Melanoma reporting to central cancer registries by US dermatologists: an analysis of the persistent knowledge and practice gap - PubMed Cartee TV et al, 2011

Melanoma Thickness and Survival Trends in the United States, 1989 to 2009 - PubMed, Shaikh et al, 2016

(4) Hospital-Based Study of Compliance with NCCN Guidelines and Predictive Factors of Sentinel Lymph Node Biopsy in the Setting of Thin Melanoma Using the National Cancer Database - PubMed Hayek et al, 2018

(5) Gene Expression Profile–Based Test to Predict Melanoma Sentinel Node Status. The MERLIN_001 Study. Tina J. Hieken et al (Jama Surgery, October 2025)

Media Contact

ICR Healthcare
Alexis Feinberg
[phone]
[e-mail]   

SkylineDx contact:

Linda Forlani
[e-mail]

 

View original content:https://www.prnewswire.co.uk/news-releases/skylinedx-launches-a-guideline-informed-risk-assessment-initiative-to-support-slnb-decision-making-in-early-stage-melanoma-302705276.html